Today: 18 November 2025
Subscribe
Browse Category

Health Technology News 12 August 2025 - 4 November 2025

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Company Overview: Telehealth for High-Acuity Care VSee Health, Inc. is a Silicon Valley-founded telehealth technology and services provider specializing in high-acuity virtual care. Founded in 2008 by Dr. Milton Chen, VSee built a secure video telemedicine platform so robust it was even utilized by NASA for astronaut healthcare businesswire.com. Today, after merging with iDoc Telehealth via a SPAC deal in mid-2024, VSee offers an integrated suite of telehealth solutions for hospitals and health systems. The company’s headquarters are in Massachusetts, and it has ~154 employees as of 2025 finviz.com. Business Model: VSee’s platform combines telehealth software with physician services to
4 November 2025
 ·  ·  ·  ·  · 
DexCom Stock Plunge Raises Big Questions – Will This Diabetes Tech Leader Rebound?

DexCom Stock Plunge Raises Big Questions – Will This Diabetes Tech Leader Rebound?

Latest News: Earnings Beat Marred by Growth Jitters DexCom’s Q3 2025 earnings (reported Oct. 30) were better than expected, but the celebration was short-lived. The headline numbers were strong – $1.209 B revenue (+22% YoY) and $0.61 adjusted EPS – beating consensus on both investing.com. In fact, demand for DexCom’s G7 continuous glucose monitors (CGMs) drove 20% organic growth globally, with U.S. sales up 21% and international up 18% YoY investing.com. Off the back of this strength, management raised full-year 2025 guidance, now targeting ~$4.63 B revenue (~15% growth) investors.dexcom.com and improved operating margins around 20–21%. However, on the earnings call DexCom’s
31 October 2025
 ·  ·  ·  ·  · 
NASA’s “Astronaut Avatars” – Tiny Organ Chips Poised to Protect Artemis II Crew’s Health

NASA’s “Astronaut Avatars” – Tiny Organ Chips Poised to Protect Artemis II Crew’s Health

What Are NASA’s “Avatars for Astronaut Health”? NASA’s “Avatars for Astronaut Health” is a bold initiative to send small living models of astronauts’ organs into deep space. These “avatars” aren’t robots or holograms – they are organ-on-a-chip devices containing real human cells, designed to mimic the functions of human tissues science.nasa.gov. For Artemis II, NASA will load chips with cells donated by the four crew members themselves, essentially creating miniaturized versions of their organ tissue that can be studied in parallel with the crew science.nasa.gov science.nasa.gov. The goal is to see how these cells respond to deep space conditions – such
16 September 2025
 ·  ·  ·  · 
Apple’s 2025 Wearables Unveiled: Hypertension Alerts, AI Translation, and More

Apple’s 2025 Wearables Unveiled: Hypertension Alerts, AI Translation, and More

Apple’s Big Bet on Health: Blood Pressure Alerts and Sleep Scores Apple’s newest watches mark a significant leap in personal health monitoring. The headline feature, hypertension notification, turns the Apple Watch into a passive blood pressure sentinel. Rather than measure absolute blood pressure values like a traditional cuff, the watch uses subtle signals from its optical heart-rate sensor to gauge how your blood vessels react with each heartbeat apple.com. Over a 30-day period, it applies a machine-learning algorithm (trained on data from over 100,000 people and validated in a 2,000-subject clinical study) to detect patterns indicative of chronically elevated blood
14 September 2025
 ·  ·  ·  ·  · 
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth up to $645 million including $120 million upfront and up to $525 million in milestones. NextRNA Therapeutics announced on August 11 it is winding down operations after cash constraints, leaving about 27 employees. FDA approved ketamine (brand name KETARx) from PharmaTher Holdings for surgical anesthesia
12 August 2025
 ·  ·  ·  · 
Go toTop